{"id":"el219","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"EL219 is a TLR7 agonist that stimulates toll-like receptor 7 signaling to enhance innate immune activation and promote anti-tumor immunity. By triggering pattern recognition receptors on immune cells, it aims to generate robust immune responses against malignant cells. The drug is being developed as a potential therapeutic for various cancers through immune system activation.","oneSentence":"EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:36:50.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EL219","genericName":"EL219","companyName":"Elion Therapeutics, Inc.","companyId":"elion-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer. Used for Solid tumors (Phase 2 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}